Kinase News and Research

RSS

Boehringer Ingelheim files MAA with EMA for afatinib approval

Today, Boehringer Ingelheim has announced the submission of a Marketing Authorisation Application to the European Medicines Agency (EMA) for approval of afatinib, the first irreversible ErbB Family Blocker, as a treatment for patients with EGFR (ErbB1) mutation positive non-small cell lung cancer (NSCLC). Afatinib has demonstrated unprecedented efficacy versus chemotherapy in the Phase III LUX-Lung 3 registration trial, which provides pivotal support for this submission.

20 Sep 2012

Pfizer announces that 14 abstracts for tofacitinib to be presented at ACR/ARHP annual meeting

Pfizer Inc. announced today that 14 abstracts for tofacitinib, an investigational oral Janus kinase (JAK) inhibitor for the treatment of adults with moderate-to-severe active rheumatoid arthritis (RA), will be presented at the American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) 2012 Annual Meeting, which is being held November 9-14 in Washington, D.C.

18 Sep 2012

Important data from Pfizer’s lung cancer and RCC portfolios to be presented at ESMO Congress

Pfizer Oncology today announced that important data from its lung cancer and renal cell carcinoma (RCC) portfolios will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress in Vienna, Austria, September 28 - October 2, 2012.

18 Sep 2012

Novel drug combination for patients with NRAS-mutant melanoma

A new study published online in Nature Medicine, led by scientists at The University of Texas MD Anderson Cancer Center, describes the discovery of a novel drug combination aimed at a subset of melanoma patients who currently have no effective therapeutic options.

17 Sep 2012

MVK mutations linked to disseminated superficial actinic porokeratosis

A Chinese research team, led by Anhui Medical University and BGI, has found the strong genetic evidences of mevalonate kinase gene (MVK) mutations link to disseminated superficial actinic porokeratosis (DSAP).

17 Sep 2012

‘C’ variant disrupts brain connectivity in children with ASD

Over the past decade, researchers have made great strides in identifying genes that lead to an increased risk of autism spectrum disorders (ASD), which result in a continuum of social deficits, communication difficulties and cognitive delays. But it's still critical to determine how exactly these genetic risk factors impact the brain's structure and function so that better treatments and interventions can be developed.

15 Sep 2012

Objective response rate promising after crizotinib for NSCLC

More than half of the latest evaluated participants from the ongoing phase II PROFILE 1005 trial of crizotinib against ALK-positive advanced non-small-cell lung cancer, achieved an objective tumor response, report researchers.

14 Sep 2012

Crizotinib may be effective treatment option for NSCLC subtype

Phase I trial results show that the chemotherapy drug crizotinib may be fast-acting and produce long-lasting treatment responses in patients with anaplastic lymphoma receptor tyrosine kinase-positive non-small-cell lung cancer.

13 Sep 2012

SOX2 gene potential therapeutic target for SCLC

Expression of the Sry-related HMG box 2 gene is higher in small-celllung cancer tissue samples than in non-cancerous lung tissue samples, according to findings from a genetic study.

13 Sep 2012

Addition of sorafenib to chemotherapy does not prolong survival

The addition of sorafenib to gemcitabine/cisplatin fails to provide any additional benefit in chemotherapy-naïve patients with nonsquamous non-small-cell lung cancer, research shows.

13 Sep 2012

Berkeley lab researchers link possible new oncogene with resistance to cancer drugs

A gene that may possibly belong to an entire new family of oncogenes has been linked by researchers with the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab) to the resistance of breast cancer to a well-regarded and widely used cancer therapy.

12 Sep 2012

New molecular pathway that leads to preeclampsia identified

Preeclampsia is one of the most dangerous conditions for the expectant mother and the unborn child and is characterized by elevated blood pressure and protein in the urine in the last trimester of pregnancy.

10 Sep 2012

Researchers identify many potential therapeutic targets for squamous cell lung cancers

A new paper published online in Nature holds out hope that people with the second most common type of lung cancer may one day benefit from targeted therapies that have transformed treatments for other lung cancer patients.

10 Sep 2012

Crizotinib effective in shrinking tumors in patients with ALK positive non-small cell lung cancer

Crizotinib is effective in shrinking tumors in patients with anaplastic lymphoma receptor tyrosine kinase (ALK) positive non-small cell lung cancer, a cancer commonly found in people who never smoked, and should be the standard of care for advanced stages of this disease, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

7 Sep 2012

Eliminating jnk3 enzyme leads to 90% reduction in Alzheimer's plaque-forming compounds

Scientists have found that eliminating an enzyme from mice with symptoms of Alzheimer's disease leads to a 90 percent reduction in the compounds responsible for formation of the plaques linked to Alzheimer's disease.

6 Sep 2012

Pfizer receives FDA approval for BOSULIF to treat Ph+ chronic myelogenous leukemia

Pfizer Inc. announced today the U.S. Food and Drug Administration (FDA) has approved BOSULIF (bosutinib), an Abl and Src kinase inhibitor, for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy.

6 Sep 2012

FDA approves Bosulif to treat chronic myelogenous leukemia

The U.S. Food and Drug Administration today approved Bosulif (bosutinib) to treat chronic myelogenous leukemia (CML), a blood and bone marrow disease that usually affects older adults.

5 Sep 2012

EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

Pfizer Inc. announced today that the European Commission (EC) has granted marketing authorization for INLYTA (axitinib) for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of kidney cancer, after failure of prior treatment with sunitinib or a cytokine.

4 Sep 2012

Scientists discover new anti-cancer and anti-metastatic molecule

A new molecule with anti-cancer and anti-metastatic properties has been discovered by teams from CNRS, CEA, the Institut Curie and Inserm, in collaboration with Australian and British researchers.

4 Sep 2012

A-kinase anchoring proteins influence levels of glucose in the body

Scientists from the United States and Sweden have discovered a new control point that could be important as a drug target for the treatment of diabetes and other metabolic diseases.

4 Sep 2012

Kinase News and Research

Boehringer Ingelheim files MAA with EMA for afatinib approval

Pfizer announces that 14 abstracts for tofacitinib to be presented at ACR/ARHP annual meeting

Important data from Pfizer’s lung cancer and RCC portfolios to be presented at ESMO Congress

Novel drug combination for patients with NRAS-mutant melanoma

MVK mutations linked to disseminated superficial actinic porokeratosis

‘C’ variant disrupts brain connectivity in children with ASD

Objective response rate promising after crizotinib for NSCLC

Crizotinib may be effective treatment option for NSCLC subtype

SOX2 gene potential therapeutic target for SCLC

Addition of sorafenib to chemotherapy does not prolong survival

Berkeley lab researchers link possible new oncogene with resistance to cancer drugs

New molecular pathway that leads to preeclampsia identified

Researchers identify many potential therapeutic targets for squamous cell lung cancers

Crizotinib effective in shrinking tumors in patients with ALK positive non-small cell lung cancer

Eliminating jnk3 enzyme leads to 90% reduction in Alzheimer's plaque-forming compounds

Pfizer receives FDA approval for BOSULIF to treat Ph+ chronic myelogenous leukemia

FDA approves Bosulif to treat chronic myelogenous leukemia

EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

Scientists discover new anti-cancer and anti-metastatic molecule

A-kinase anchoring proteins influence levels of glucose in the body

Measuring Drug-Target Residence Times with Biochemical Assays eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News